Security key
68232V884
Traws Pharma, Inc. - Common Stock, par value $0.01 per share (TRAW)
CUSIP: 68232V884
Q2 2025 13F Holders as of 30 Jun 2025
- Security type / class
- Equity / Common Stock, par value $0.01 per share
- Total 13F shares
- 1,263,487
- Total 13F value
- $1,869,962
- Share change
- -468,822
- SEC-reported price per share
- $1.48
- Number of holders
- 19
- Value change
- -$1,075,287
- Number of buys
- 6
- Number of sells
- 8
- Shares outstanding
- 16,062,541
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2025
Institutions
19
Top holders
10
TRAW full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
Previous quarter: Q1 2025
Traws Pharma, Inc. SEC filings
Traws Pharma, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 68232V884
Recent filing periods:
Ownership snapshot
Top reported holders of TRAW - Traws Pharma, Inc. - Common Stock, par value $0.01 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Alyeska Investment Group,...
Disclosed value leader
ORBIMED ADVISORS LLC
Comparable rows
15/15
Latest evidence
31 Mar 2025
13D/G
13F
Lead comparable stake: 9.9%
13D/G row: Alyeska Investment Group, L.P.
Showing 1-6 of 15 holder rows.
Quick read
Alyeska Investment Group, L.P. leads the comparable SEC ownership view at 9.9%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Alyeska Investment Group, L.P.'s linked filing trail.
Comparable ownership
Top 5
Alyeska Investment Group, L.P.
9.9%
ORBIMED ADVISORS LLC
3.8%
PERCEPTIVE ADVISORS LLC
2.6%
ADAGE CAPITAL PARTNERS GP, L.L.C.
2.1%
Vestal Point Capital, LP
1.1%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Alyeska Investment Group, L.P. |
13D/G
13F
Company
|
9.9%
|
$462,446
302,252 shares
|
$0 | 31 Dec 2024 |
| ORBIMED ADVISORS LLC |
13F
Company
|
3.8%
|
$1,392,721
605,531 shares
|
— | 31 Mar 2025 |
| PERCEPTIVE ADVISORS LLC |
13F
Company
|
2.6%
|
$970,096
421,781 shares
|
— | 31 Mar 2025 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
Company
|
2.1%
|
$759,000
330,000 shares
|
— | 31 Mar 2025 |
| Vestal Point Capital, LP |
13F
Company
|
1.1%
|
$402,500
175,000 shares
|
— | 31 Mar 2025 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
0.21%
|
$76,775
33,379 shares
|
— | 31 Mar 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
19
Shares
1,263,487
Rows available
19
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
18
Q2 2025 holders
19
Holder diff
1
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 value | Q2 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend